Group 1 - The company announced the acquisition of 100% equity and related rights of Da Zhong Tang PTE. LTD. by its subsidiary Gushengtang Singapore, marking a significant step in its overseas expansion strategy [1] - The acquisition follows a strategic partnership with a digital healthcare platform in Singapore, indicating an accelerated implementation of the company's traditional Chinese medicine (TCM) internationalization strategy [1] - Da Zhong Tang operates 14 TCM clinics in Singapore, providing a well-established local service capability and a trusted user base, which will enhance the company's market coverage and operational synergy upon completion of the acquisition [1] Group 2 - The company is leveraging vast, high-quality clinical data to accelerate the development of AI replicas of renowned doctors, aiming to transform TCM medical practices [2] - The AI system, based on deep learning algorithms, can replicate the diagnostic capabilities of top experts, facilitating the transfer of knowledge and improving the efficiency of medical resource supply [2] - The company maintains a positive outlook on its financial performance, projecting adjusted net profits of 493 million, 594 million, and 708 million for the years 2025 to 2027, supported by ongoing share buybacks and favorable industry conditions [2]
固生堂(2273.HK)：出海并购加速 回购加码彰显发展信心